BriaCell study validates Bria-OTS+ cancer therapy mechanism

BriaCell Therapeutics Corp. (NASDAQ: BCTX, TSX: BCT) announced the publication of research validating the mechanism of action for its Bria-OTS+ immunotherapy platform in JCI Insight, a peer-reviewed biomedical journal.

The study, conducted in collaboration with the National Cancer Institute, demonstrated that semi-allogeneic dendritic-cell vaccines recruit alloreactive CD4+ T-cell help through mismatched MHC class II molecules, which strengthens antigen-specific CD8+ T-cell responses against tumors.

"The study demonstrated that semi-allogeneic dendritic-cell vaccines recruit alloreactive CD4⁺ T-cell help through mismatched MHC class II molecules, which in turn strengthens antigen-specific CD8⁺ T-cell responses against tumors," said Jay A. Berzofsky, Senior Investigator of NCI and coauthor of the publication.

The research supports BriaCell's design approach for Bria-OTS+, which uses partial HLA matching for tumor-antigen presentation while planned HLA mismatching drives CD4+ helper responses. The therapy is described as a personalized, off-the-shelf, semi-allogeneic cellular immunotherapy.

Bria-OTS is based on BriaCell's lead candidate Bria-IMT, currently being evaluated in a Phase 1/2a study in patients with metastatic recurrent breast cancer. The trial includes monotherapy dose escalation and checkpoint inhibition combination dose expansion cohorts, with the company having recently progressed into the dose expansion phase.

BriaCell is a clinical-stage biotechnology company developing immunotherapies for cancer treatment. The information is based on a company press release.

You May Also Be Interested In